Patents by Inventor Sebastien Laliberte

Sebastien Laliberte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3,4-substituted piperidine derivatives as renin inhibitors
    Patent number: 8889714
    Abstract: The present invention relates to 3,4-substituted piperidinyl-based renin inhibitor compounds bearing at 4-position oxopyridine and having the formula (I). The invention further relates to pharmaceutical compositions containing said compounds, as well as their use in treating cardiovascular events and renal insufficiency.
    Type: Grant
    Filed: May 4, 2009
    Date of Patent: November 18, 2014
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Austin Chih-Yu Chen, Daniel Dube, Pierre-Andre Fournier, Erich L. Grimm, Patrick Lacombe, Sebastien Laliberte, Dwight Macdonald, D. Bruce MacKay, Daniel James McKay, Tom Yao-Hsiang Wu, Louis-Charles Campeau, Jeremy Peter Scott, Nadine Bremeyer
  • Case of renin inhibitors
    Patent number: 8343968
    Abstract: The present invention relates to piperidine-based renin inhibitor compounds having carboxylate or carboxylic acid terminal groups, and their use in treating cardiovascular events and renal insufficiency.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: January 1, 2013
    Assignee: Merck Canada Inc.
    Inventors: Tom Yao-Hsiang Wu, Helene Juteau, Michel Gallant, Daniel Dube, Patrick Roy, Renee Aspiotis, Erich I. Grimm, Sebastien Laliberte, Austin Chen
  • RENIN INHIBITORS
    Publication number: 20120190701
    Abstract: Renin inhibitors, which are spirocyclic piperidine amides, of structural formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency. wherein n, for each instance in which it occurs, is independently 0, 1, or 2; R1 is hydrogen, C1-6-alkyl or C3-6-cycloalkyl, wherein said C1-6-alkyl or C3-6-cycloalkyl group can be independently substituted with 1-3 halogens; A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to another five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is a bond or —(C?O)—, —CH(OH)—, —CH2—or ?CH—; U is a bond or —CH2-, or for the case when V is ?CH—, U is —CH?; X is ?CH—, ?CF—, ?C(OR3)—, or —C?O—; and Y is ?CH—, ?CF—, ?N—, or for the case when X is —C?O—, Y is —N(R3)—.
    Type: Application
    Filed: August 17, 2010
    Publication date: July 26, 2012
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Austin Chih-Yu Chen, Sebastien Laliberte, Guillaume Larouche, Yongxin Han, Daniel McKay
  • RENIN INHIBITORS
    Publication number: 20120035214
    Abstract: The present invention relates to biaryl piperidine-based renin inhibitor compounds, and their use in treating cardiovascular events and renal insufficiency.
    Type: Application
    Filed: April 1, 2010
    Publication date: February 9, 2012
    Applicants: Merck Canada Inc., Merck Sharp & Dohme Corp.
    Inventors: Daniel J. McKay, Melissa Arbour, Renee Aspiotis, Austin Chen, Pierre-Andre Fournier, Michel Gallant, Yongxin Han, Helene Juteau, Patrick Lacombe, Sebastien Laliberte, Sophie Lauzon, Carmela Molinaro, Paul O'Shea, Yeeman Ramtohul, Daniel Simard, Dwight MacDonald, Bruce Mackay, Christophe Mellon, Krista Morley, Chit Tsui, Sarah Jennifer Dolman, Greg Hughes, Jacob Janey
  • Renin inhibitors
    Patent number: 8076359
    Abstract: The present invention relates to disubstituted piperidinyl renin inhibitor compounds having the structure (Formula I) and their use in treating cardiovascular events and renal insufficiency.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: December 13, 2011
    Assignee: Merck Canada Inc.
    Inventors: Daniel Dube, Michel Gallant, Erich L. Grimm, Helene Juteau, Sebastien Laliberte, Tom Yao-Hsiang Wu
  • RENIN INHIBITORS
    Publication number: 20110237622
    Abstract: The present invention relates to 3,4-substituted piperidinyl—based renin inhibitor compounds bearing at 4-position oxopyridine or Isoquinolone and having the formula (I): wherein S is Formula (IIa) or Formula (IIb). The invention further relates to pharmaceutical compositions containing said compounds, as well as their use in treating cardiovascular events and renal insufficiency.
    Type: Application
    Filed: December 8, 2009
    Publication date: September 29, 2011
    Applicant: Merck Frosst Canada LTD.
    Inventors: Austin Chih-Yu Chen, Daniel Dube, Pierre-Andre Fournier, Erich L. Grimm, Patrick Lacombe, Sebastien Laliberte, Dwight Macdonald, D. Bruce Mackay, Daniel James Mckay, Tom Yao-Hsiang Wu
  • 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS
    Publication number: 20110152316
    Abstract: The present invention relates to 3,4-substituted piperidinyl-based renin inhibitor compounds bearing at 4-position Isoqumolone and having the Formula (I): The invention further relates to pharmaceutical compositions containing said compounds, as well as their use in treating cardiovascular events and renal insufficiency.
    Type: Application
    Filed: May 21, 2009
    Publication date: June 23, 2011
    Inventors: Austin Chih-Yu Chen, Daniel Dube, Pierre-Andre Fournier, Erich L. Grimm, Patrick Lacombe, Sebastien Laliberte, Dwight MacDonald, D. Bruce MacKay, Daniel James McKay, Tom Yao-Hsiang Wu
  • Pharmaceutical phenylquinoline and chromen-2-one triazole compounds
    Patent number: 7960409
    Abstract: The instant invention provides compounds of Formula I which are leukotriene biosynthesis inhibitors. Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: June 14, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Erich L. Grimm, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Helene Juteau, Sebastien Laliberte, Bruce MacKay, Yves Gareau
  • 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS
    Publication number: 20110053940
    Abstract: The present invention relates to 3,4-substituted piperidinyl-based renin inhibitor compounds bearing at 4-position oxopyridine and having the formula (I). The invention further relates to pharmaceutical compositions containing said compounds, as well as their use in treating cardiovascular events and renal insufficiency.
    Type: Application
    Filed: May 4, 2009
    Publication date: March 3, 2011
    Inventors: Austin Chih-Yu Chen, Daniel Dube, Pierre-Andre Fournier, Erich L. Grimm, Patrick Lacombe, Sebastien Laliberte, Dwight MacDonald, D. Bruce MacKay, Daniel James McKay, Tom Yao-Hsiang Wu, Louis-Charles Campeau, Jeremy Peter Scott, Nadine Bremeyer
  • NOVEL CASE OF RENIN INHIBITORS
    Publication number: 20100120859
    Abstract: The present invention relates to piperidine-based renin inhibitor compounds having carboxylate or carboxylic acid terminal groups, and their use in treating cardiovascular events and renal insufficiency.
    Type: Application
    Filed: May 23, 2008
    Publication date: May 13, 2010
    Applicant: MERCK FROSST CANADA LTD.
    Inventors: Tom Yao-Hsiang Wu, Helene Juteau, Michel Gallant, Daniel Dube, Patrick Roy, Renee Aspiotis, Erich L. Grimm, Sebastien Laliberte, Austin Chen
  • RENIN INHIBITORS
    Publication number: 20100063091
    Abstract: The present invention relates to disubstituted piperidinyl renin inhibitor compounds having the structure (Formula I) and their use in treating cardiovascular events and renal insufficiency.
    Type: Application
    Filed: November 14, 2007
    Publication date: March 11, 2010
    Inventors: Daniel Dube, Michel Gallant, Erich L. Grimm, Helene Juteau, Sebastien Laliberte, Tom Yao-Hsiang Wu
  • Novel Pharmaceutical Compounds
    Publication number: 20090227638
    Abstract: The instant invention provides compounds of Formula (Ia) which are leukotriene biosynthesis inhibitors, wherein X is O or S, Y is O, S, —NR6—CHR7— or —NR8—C(O)— and A is selected from 5-membered aromatic heterocyclic ring, 6-membered aromatic heterocyclic ring, naphthelenic or heterobicyclic aromatic ring system, phenyl and benzyl. A is optionally mono- or disubstituted. Compounds of Formula (Ia) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Application
    Filed: March 21, 2006
    Publication date: September 10, 2009
    Inventors: Marc Blouin, Erich L. Grimm, Yves Gareau, Marc Gagnon, Helene Juteau, Sebastien Laliberte, Bruce MacKay, Richard Friesen
  • Pharmaceutical compounds
    Patent number: 7553973
    Abstract: The instant invention provides compounds of Formula Ia which are leukotriene biosynthesis inhibitors. Compounds of Formula Ia are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: June 30, 2009
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Marc Blouin, Erich L. Grimm, Yves Gareau, Marc Gagnon, Helene Juteau, Sebastien Laliberte, Bruce MacKay, Richard Friesen
  • Novel pharmaceutical compounds
    Publication number: 20090030048
    Abstract: The instant invention provides compounds of Formula Ia which are leukotriene biosynthesis inhibitors. Compounds of Formula Ia are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Application
    Filed: June 27, 2008
    Publication date: January 29, 2009
    Inventors: Marc Blouin, Erich L. Grimm, Yves Gareau, Marc Gagnon, Helene Juteau, Sebastien Laliberte, Bruce MacKay, Richard Friesen
  • 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors
    Patent number: 7439260
    Abstract: The instant invention provides compounds of Formula (I) which are leukotriene biosynthesis inhibitors. Compounds of formula (I) are useful as anti-asthmatic, anti-allergic, anti-inflammatory, cytoprotective and anti-artherosclerotic agents.
    Type: Grant
    Filed: June 8, 2004
    Date of Patent: October 21, 2008
    Assignee: Merck Forsst Canada & Co.
    Inventors: Yves Gareau, Helene Juteau, D. Bruce MacKay, Richard Friesen, Erich L. Grimm, Marc Blouin, Sebastien Laliberte
  • Novel pharmaceutical compounds
    Publication number: 20080188521
    Abstract: The instant invention provides compounds of Formula I which are leukotriene biosynthesis inhibitors. Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Application
    Filed: February 1, 2008
    Publication date: August 7, 2008
    Inventors: Erich L. Grimm, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Helene Juteau, Sebastien Laliberte, Bruce MacKay, Yves Gareau
  • Novel pharmaceutical compounds
    Publication number: 20070149579
    Abstract: The instant invention provides compounds of Formula Ia which are leukotriene biosynthesis inhibitors. Compounds of Formula Ia are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Application
    Filed: March 21, 2006
    Publication date: June 28, 2007
    Inventors: Marc Blouin, Erich Grimm, Yves Gareau, Marc Gagnon, Helene Juteau, Sebastien Laliberte, Bruce MacKay, Richard Friesen
  • 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors
    Publication number: 20060116406
    Abstract: The instant invention provides compounds of Formula (I) which are leukotriene biosynthesis inhibitors. Compounds of formula (I) are useful as anti-asthmatic, anti-allergic, anti-inflammatory, cytoprotective and anti-artherosclerotic agents.
    Type: Application
    Filed: June 8, 2004
    Publication date: June 1, 2006
    Inventors: Yves Gareau, Helene Juteau, D. Bruce MacKay, Richard Friesen, Erich Grimm, Marc Blouin, Sebastien Laliberte
  • Use of phosphodiesterase-4 inhibitors as enhancers of cognition
    Publication number: 20060040981
    Abstract: The present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of a phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a safe and effective amount of a phosphodiesterase-4 inhibitor.
    Type: Application
    Filed: November 19, 2003
    Publication date: February 23, 2006
    Inventors: Daniel Dube, Michel Gallant, Patrick Lacombe, Yves Girard, Dwight Macdonald, Richard Friesen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte, Annette Robichaud, Anthony Mastracchio, Helene Perrier
  • Alkyne-aryl phosphodiesterase-4 inhibitors
    Publication number: 20050070569
    Abstract: Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation.
    Type: Application
    Filed: August 27, 2002
    Publication date: March 31, 2005
    Inventors: Daniel Guay, Mario Girard, Pierre Hamel, Sebastien Laliberte, Richard Friesen